respiratory pathogens
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia
The treatment is to protect children under two years of age from respiratory syncytial virus
Study shows infants given RSV vaccination benefit beyond first RSV season
The RSV virus is highly contagious and can cause serious respiratory illness for infants
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
Osivax initiates phase 2b trial of influenza A vaccine candidate
The study aims to enrol 2,850 participants across 16 sites in Europe
Invivyd working with FDA towards potential Biologics License Application for COVID-19
The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment
FDA approves Pfizer and BioNTech’s jab for COVID-19
Globally, five billion doses of the companies’ vaccine have been distributed
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition
The deal includes an early-stage combination vaccine candidate for RSV and hMPV
Moderna shares positive phase 3 results for mRNA flu vaccine candidate
More than 600,000 people in the US were hospitalised due to flu-related illness last year
Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults
The vaccine is already approved in the US for use in adults aged 60 years and older